LONDON—Argenta Discovery Ltd., the pharmaceutical R&D group, announced that it entered into a fee-for-service collaboration with Antisoma plc. Under the terms of the agreement, scientists from the two organizations will work together to develop improved molecules for Antisoma's program of telomere targeting agents (TTAs). Antisoma will utilize Argenta's expertise in medicinal chemistry, computer-aided drug design, molecular biology, biochemistry, assay development and in vitro screening, during the course of the collaboration.

"Antisoma's decision to work with us confirms our contract research team's experience in undertaking integrated, oncology-focused programs, and underlines Argenta's ongoing commitment to providing first-class contract R&D services to leading organizations in the pharmaceutical industry," says Dr. Christopher Ashton, Argenta's CEO.
Medivir, Presidio amend license agreement